AIM: To investigate the role of matrix metalloproteinases (MMPs) in the responses of rats to a prolonged doxorubicin (DOX) treatment. METHODS: Male Wistar rats were used. DOX was administered by intraperitoneal injections of seven doses (cumulative dose was 15 mg/kg). Control animals were treated with saline. Tissue or plasma samples were collected at four and eight weeks after the application of the last dose. Protein levels were determined by immunoblot assay, and MMP activities were measured by gelatin zymography. Superoxide content was analyzed using a lucigenin chemiluminescence assay and superoxide dismutase (SOD) activities with a SOD assay kit. Qualitative structural alterations of the heart were characterized by transmission electron microscopy. RESULTS: Systolic blood pressure was higher in DOX-treated rats as compared with the control rats at 8 weeks after treatment. In contrast, there were no differences in the heart rate between the control and DOX-treated rats. DOX treatment caused marked heterogeneous subcellular alterations of cardiomyocytes and structural disorganizations of the cardiac extracellular space. The effects of DOX were linked to a stimulation of plasma MMP-2 and MMP-9 activities that had already increased by 4 weeks after the end of the treatment. In the left ventricle, however, DOX only led to increased MMP-2 activation at 8 weeks after the end of treatment. These changes in tissue MMP-2 were connected with stimulation of Akt kinase activation, inhibition of SOD, an increase in superoxide levels, induction of iNOS protein expression and caspase-3 activation. CONCLUSION: Our results show that MMPs are involved in the chronic cardiotoxicity of DOX in rats. The data also suggest that reactive oxygen species (superoxide), NO production (iNOS) and the Akt kinase pathway can modulate MMP-2 activities in rat hearts influenced by DOX.
AIM: To investigate the role of matrix metalloproteinases (MMPs) in the responses of rats to a prolonged doxorubicin (DOX) treatment. METHODS: Male Wistar rats were used. DOX was administered by intraperitoneal injections of seven doses (cumulative dose was 15 mg/kg). Control animals were treated with saline. Tissue or plasma samples were collected at four and eight weeks after the application of the last dose. Protein levels were determined by immunoblot assay, and MMP activities were measured by gelatin zymography. Superoxide content was analyzed using a lucigenin chemiluminescence assay and superoxide dismutase (SOD) activities with a SOD assay kit. Qualitative structural alterations of the heart were characterized by transmission electron microscopy. RESULTS: Systolic blood pressure was higher in DOX-treated rats as compared with the control rats at 8 weeks after treatment. In contrast, there were no differences in the heart rate between the control and DOX-treated rats. DOX treatment caused marked heterogeneous subcellular alterations of cardiomyocytes and structural disorganizations of the cardiac extracellular space. The effects of DOX were linked to a stimulation of plasma MMP-2 and MMP-9 activities that had already increased by 4 weeks after the end of the treatment. In the left ventricle, however, DOX only led to increased MMP-2 activation at 8 weeks after the end of treatment. These changes in tissue MMP-2 were connected with stimulation of Akt kinase activation, inhibition of SOD, an increase in superoxide levels, induction of iNOS protein expression and caspase-3 activation. CONCLUSION: Our results show that MMPs are involved in the chronic cardiotoxicity of DOX in rats. The data also suggest that reactive oxygen species (superoxide), NO production (iNOS) and the Akt kinase pathway can modulate MMP-2 activities in rat hearts influenced by DOX.
Authors: Anna Spániková; Monika Ivanová; Jana Matejíková; Tána Ravingerová; Miroslav Barancík Journal: Gen Physiol Biophys Date: 2010-03 Impact factor: 1.512
Authors: Andreas Goetzenich; Nima Hatam; Alma Zernecke; Christian Weber; Tanja Czarnotta; Rüdiger Autschbach; Stefan Christiansen Journal: J Heart Lung Transplant Date: 2009-10 Impact factor: 10.247
Authors: Michele M Castro; Elen Rizzi; Lívia Figueiredo-Lopes; Karla Fernandes; Lusiane M Bendhack; Dimitrius Leonardo Pitol; Raquel F Gerlach; Jose E Tanus-Santos Journal: Atherosclerosis Date: 2007-12-03 Impact factor: 5.162
Authors: Tan Panpan; Du Yuchen; Shi Xianyong; Liu Meng; He Ruijuan; Dong Ranran; Zhang Pengyan; Li Mingxi; Xie Rongrong Journal: Cardiovasc Toxicol Date: 2022-07-25 Impact factor: 2.755
Authors: Merry L Lindsey; Richard A Lange; Helen Parsons; Thomas Andrews; Gregory J Aune Journal: Am J Physiol Heart Circ Physiol Date: 2014-09-12 Impact factor: 4.733
Authors: I Dovinova; M Kvandová; P Balis; L Gresova; M Majzunova; L Horakova; J Yh Chan; M Barancik Journal: Physiol Res Date: 2020-12-31 Impact factor: 1.881
Authors: Ekaterina Yu Podyacheva; Ekaterina A Kushnareva; Andrei A Karpov; Yana G Toropova Journal: Front Pharmacol Date: 2021-06-03 Impact factor: 5.810